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The pharmacokinetics of zidovudine (ZDV) are established in patients with various stages of human
immunodeficiency virus (HIV) disease. This study was conducted to determine the pharmacokinetic parame-
ters of ZDV in patients with asymptomatic HIV infection and liver disease. HIV-infected volunteers with
normal renal function were stratified according to the severity of liver disease (seven of eight were classified
as mild). Each subject received a single intravenous dose of ZDV (120 mg) on the first day, followed by a single
oral dose of ZDV (200 mg) on the second day. Blood samples were obtained over an 8-h collection interval, and
concentrations of ZDV and its glucuronidated metabolite (GZDV) were determined by high-performance liquid
chromatography. The following pharmacokinetic parameters were obtained after oral administration of ZDV
to HIV-infected patients with mild hepatic disease; these values were compared with previously reported data
in healthy volunteers. The area under the curve (AUC) (1,6706 192 ng z h/ml), maximum concentration of drug
in serum (1,751 6 180 ng/ml), and half-life (2.04 6 0.38 h) of ZDV were increased, while the apparent oral
clearance (1.57 6 0.31 liter/h/kg of body weight) was decreased; AUC (7,685 6 1,222 ng z h/ml) and maximum
concentration of drug in serum (5,220 6 1,350 ng/ml) of GZDV and the AUC ratio of GZDV to ZDV (2.79 6
0.43) after oral administration were decreased. ZDV absolute bioavailability was 0.75 6 0.15 in HIV-infected
patients with mild hepatic disease. Although the ZDV apparent oral clearance was not impaired as significantly
as in patients with biopsy-proven cirrhosis, our results suggest that ZDV could accumulate in HIV-infected
patients with mild hepatic disease because of impaired formation of GZDV. Patients with mild hepatic disease
may require dosage adjustment to avoid accumulation of ZDV after extended therapy.
Zidovudine (ZDV) has demonstrated clinical efficacy with
decreased morbidity and mortality in patients with asymptom-
atic or more severe human immunodeficiency virus (HIV) dis-
ease (4, 7). Although data support the use of ZDV in selected
patients, the drug is associated with significant toxicity in ad-
vanced HIV disease which is most commonly manifested by
suppression of the circulating erythrocyte and neutrophil
counts (18). Individual patients exhibit substantial variability in
their ability to tolerate chronic ZDV treatment.
The pharmacokinetic disposition of ZDV in HIV-infected
patients without evidence of hepatic disease has been de-
scribed previously (1, 3, 12). ZDV was rapidly absorbed; the
time to reach peak concentrations in plasma ranged from 0.6 to
0.8 h. The average oral bioavailability was about 65%, with 17
to 23% of an intravenous (i.v.) dose excreted unchanged in the
urine. The volume of distribution at steady state was approx-
imately 1.4 liters/kg of body weight, the average total body
clearance (CL) was 1.3 to 1.6 liters/h/kg, and the elimination
half-life (t1/2) of ZDV was approximately 1 h. Approximately
60% of an i.v. dose was recovered as 39-azido-39-deoxy-59 glu-
curonylthymidine (GZDV) in urine. After oral dosing, about
14% and 75% of the dose were recovered in urine as ZDV and
GZDV, respectively.
ZDV is eliminated primarily by hepatic conjugation to an
inactive glucuronyl derivative, GZDV. Glucuronidation activ-
ity has been thought to be preserved in various types of liver
disease (20). However, current evidence suggests that glucuron-
idation of some substances may be impaired in hepatic dys-
function. For example, the hepatic extraction of morphine, a
drug that is rapidly cleared and extensively glucuronidated, was
reduced 25% in eight male patients with biopsy-proven etha-
nol-induced cirrhosis compared with controls (5). Additional
observations suggested that the reduction in morphine’s he-
patic extraction ratio was a consequence of impaired hepatic
enzyme capacity as opposed to decreased liver blood flow.
The disposition of ZDV is similar to morphine. ZDV is not
extensively protein bound (,25%), and the CL of ZDV in
humans is approximately 1,900 ml/min/70 kg of body weight,
similar to hepatic blood flow (1). The oral clearance (CL/F,
where F is absolute bioavailability) of ZDV and the formation
clearance of GZDV were decreased in HIV-seronegative pa-
tients with biopsy-proven liver cirrhosis compared with HIV-
seronegative controls (22). Decreased elimination of ZDV be-
cause of liver dysfunction may be particularly common among
HIV-infected hemophiliacs and i.v. drug users who have a high
frequency of chronic hepatitis due to infection with other
blood-borne viruses. Patients with opportunistic infections
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such as disseminated Mycobacterium avium complex or cyto-
megalovirus also may exhibit evidence of liver damage, and
thus these patients may have altered ZDV pharmacokinetics,
possibly leading to an increased risk of toxicity (2, 11).
AIDS Clinical Trial Group Protocol 062 was designed to
examine the influence of hepatic disease on the pharmacoki-
netics and bioavailability of ZDV administered to asymptom-
atic HIV-infected patients. Results are compared with data
obtained from HIV-seronegative cirrhotic patients, HIV-in-
fected hemophiliacs with abnormal liver function tests, and
HIV-infected patients and seronegative volunteers without ev-
idence of liver disease (8, 13, 14, 22).
MATERIALS AND METHODS
Subjects. Eight volunteers with HIV infection and biochemical evidence of
hepatic disease were enrolled in the study after written informed consent was
obtained. This open-label study was approved by the Committee on the Protec-
tion of the Rights of Human Subjects for each institution. Participating centers
included the University of North Carolina, University of Washington, University
of Massachusetts, and Hershey Medical Center. Eligible patients were those with
a Karnofsky performance scale of 60 or greater, 18 years of age or older,
documentation of HIV infection by enzyme-linked immunosorbent assay with
confirmation by Western blotting (immunoblotting), and laboratory or clinical
evidence of hepatic disease. The subjects were stratified according to the results
of commonly available liver function tests performed within 7 days of the study
and the absence or presence of ascites (Table 1). Exclusion criteria included the
presence of active opportunistic infections (with the exception of active or
chronic hepatitis B virus or hepatitis delta virus infection) or ongoing therapy for
an opportunistic infection, a platelet count of ,50,000/mm3, a polymorphonu-
clear leukocyte count of ,1,000/mm3, a creatinine concentration of .1.5 mg/dl,
acute viral hepatitis within 30 days of study, cytotoxic chemotherapy or radiation
therapy for Kaposi’s sarcoma within 30 days of study, active drug or alcohol
abuse, women taking birth control pills, pregnant women or women who are
breast feeding, and patients on concomitant medications. Prior treatment with
ZDV was not an exclusion if ZDV had been discontinued at least 48 h prior to
study. Factor concentrate therapy was not an exclusion; all other medications
were discontinued 48 h prior to the study. Each subject underwent a medical
history review, physical examination, and laboratory evaluation within 1 week
prior to commencement of the study. Liver function tests were repeated on the
first day of the study. Follow-up evaluation 1 to 2 weeks after study doses were
administered included a medical history, physical examination, and laboratory
evaluation.
Drug administration. Two independent venous access sites were established—
one for drug infusion and the other for blood sampling. Each subject received a
single 120-mg i.v. dose of ZDV in 150 ml of 5% dextrose infused over 30 min on
day 1. On day 2, a single 200-mg oral dose of ZDV (two 100-mg capsules) was
administered with 200 ml of water. All subjects fasted for 8 h prior to each dose
and for 2 h after each dose.
Sample collection. Blood samples (5 ml) were collected at the following times
on days 1 and 2: 0 min (preinfusion or just prior to oral dose); 15 and 30 min (end
of i.v. infusion); and 45, 60, 90, 120, 150, 180, 210, 240, 360, and 480 min after the
beginning of the dose. The samples were centrifuged, and the serum was col-
lected and frozen at 2208C.
Drug analysis. Before analysis, samples were heat inactivated at 56 to 588C for
30 min. Concentrations of ZDV and GZDV in serum were determined by a
high-performance liquid chromatography (HPLC) assay developed by Good et
al. (10) with modifications (23, 26, 27). Briefly, both ZDV and GZDV were
extracted on lipophilic type W columns with a DuPont Prep I automated sample
processor (DuPont Co., Wilmington, Del.); each sample (0.5 ml) was placed on
a column, washed with phosphate-buffered saline, and eluted with methanol. The
methanol was evaporated, and the residue was reconstituted with 15% acetoni-
trile in water and injected into the HPLC. The column was a C18-Resolve column
(5 mm particle size; Waters Associates, Milford, Mass.). The mobile phase was
15% acetonitrile in 0.025 M potassium phosphate buffer (pH 2.20) at a flow rate
of 1 ml/min. To reduce the chance of measuring an interfering substance co-
eluting with either ZDV or GZDV, the peaks eluting from the column were
simultaneously measured at 266 and 254 nm. The ratio of peak heights at these
wavelengths was compared with the corresponding ratios in the calibration sam-
ple and controls included in each assay batch. When the ratio in a patient’s
specimen differed by more than 10% (indicating a coeluting impurity), it was
reassayed with a mobile phase with a higher pH (e.g., pH 2.5). The lower limits
of detection were 0.04 mM ZDV and 0.05 mM GZDV. Interassay precision
values (as percentage coefficients of variation) were 5% (3.6 mM), 5% (0.36 mM),
and 19% (0.08 mM) for ZDV and 10% (2.1 mM), 13% (0.21 mM), and 14% (0.12
mM) for GZDV.
Pharmacokinetic analysis.Data were analyzed by noncompartmental methods
with PCNONLIN version 4.2 model 200 for extravascular (oral) input and model
202 for i.v. infusion input. The terminal elimination rate constant (lz) was
calculated from the slope of linear regression (least-squares method) of the
logarithm of serum drug concentrations as a function of time in the terminal
elimination phase. After visual inspection of the concentration-time profiles, 150
min (after i.v. administration) and 180 min (after oral administration) were
selected as the first points for the calculation of lz. With only a few exceptions,
five and six datum points were used to determine the terminal phase of elimi-
nation after oral and i.v. administration, respectively. The terminal t1/2 was
calculated as 0.693/lz. PCNONLIN uses the linear trapezoidal method to cal-
culate area under the concentration (in serum)-time curve (AUC) from time
zero to the time of the last sample (AUClast) and is extrapolated to infinity. Other
pharmacokinetic parameters were determined for ZDV and GZDV by standard
noncompartmental methods (9, 19). The maximum concentration (Cmax) and the
time to achieve the maximum concentration (Tmax) were obtained by visual
inspection of each subject’s serum drug concentration-time profile. The absolute
bioavailability (F) was calculated by the equation (i.v. dose/oral dose) 3 (oral
AUC/i.v. AUC). The AUC ratio of GZDV to ZDV was calculated with adjust-
ment for the molecular weights of GZDV and ZDV (443 and 267, respectively).
Data are reported as means 6 standard deviations unless stated otherwise.
TABLE 1. Patient laboratory values and demographicsa
Patient Site Groupb Wt(kg)
Age








other characteristics Clinical sign(s)




2 UM A 59 26 F 74 0.6 12.4 4.0 Hepatitis nonA, nonB None
3 UM A 81.4 31 M 131 0.6 11.8 4.5 HBsAg, anti-HBc, anti-HDV,
chronic active hepatitis B,
and delta virus/ITP
Palmar erythema
4 HMC A 73.2 28 M 175 0.6 11.4 3.9 Hemophilia A None
5 HMC A 86.3 50 M 168 1.2 11.9 4.7 HBsAg, hemophilia A None
6 UNC A 86.7 28 M 60 0.4 13.2 4.1 HBsAg None
7 UNC B 95 37 M 148 1.1 11.3 4.2 Anti-HBs, anti-HBc None




a Abbreviations: M, male, F, female; ALT, alanine aminotransferase; TB, total bilirubin; PT, prothrombin time; AST, aspartate aminotransferase; Alb, albumin;
anti-HBs, hepatitis b virus surface antibody; anti-HBc, hepatitis b virus core antibody; HBsAg, hepatitis B virus surface antigen; anti-HDV, hepatitis delta virus
antibody; HMC, Hershey Medical Center; UNC, University of North Carolina; UM, University of Massachusetts; UW, University of Washington.
b Group A, 1 3 upper limit of normal (ULN) , ALT , 5 3 ULN; group B, 5 3 ULN # ALT , 10 3 ULN, TB, ,1.5 mg/dl, PT, ,2 s prolonged, no signs of clinical
hepatic disease; group E, ALT $ 30 3 ULN, or TB $5 mg/dl, or PT $5 s prolonged, or presence of clinical signs (e.g., ascites, varices, or other evidence of portal
hypertension, or hepatic encephalopathy).
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RESULTS
Liver disease category and demographic and laboratory data
for each patient are shown in Table 1. Seven of eight subjects
had mild hepatic disease (disease category A or B). One pa-
tient was classified as category E (severe liver disease) because
of evidence of portal hypertension. If categorized according to
Pugh’s modification of Child’s classification (15), seven of the
eight subjects had mild dysfunction (Child-Pugh score, >5)
and patient 8 had moderate dysfunction (Child-Pugh score,
>7). The mean body weight of the eight subjects was 78.03 6
11.50 kg (range, 59 to 95 kg). The mean age of the subjects was
34.5 6 8.8 years. One female participated in this trial.
The drug concentration-time profiles (patient 3) for ZDV
and GZDV obtained after oral and i.v. administration are
shown in Fig. 1. The figure shows drug concentrations with
linear (top panel) and logarithmic (bottom panel) coordinates.
In all cases, the terminal portion of the GZDV serum drug
concentration-time profile paralleled the decline of serum
ZDV concentrations, indicating formation rate-limited elimi-
nation of the metabolite. Higher concentrations of GZDV
were observed relative to ZDV concentrations after oral ad-
ministration, consistent with hepatic first-pass extraction of
ZDV.
Pharmacokinetic parameters after i.v. and oral ZDV admin-
istration are presented in Table 2. Table 3 shows the pharma-
cokinetic parameters for GZDV after ZDV administration.
FIG. 1. Serum drug concentration-time profiles (patient 3) of ZDV and GZDV after oral (left) and i.v. (right) ZDV administration.
TABLE 2. Pharmacokinetic parameters after ZDV administrationa
Treatment Patient AUC0–`(ng z h/ml)
Cmax





ZDV (120 mg i.v.) 1 1,532 1,330 0.50 3.08 2.38 1.12 2.67
2 1,179 1,100 0.25 1.85 1.45 1.72 2.51
3 1,189 1,360 0.50 1.89 1.36 1.24 1.68
4 993 1,000 0.25 1.65 1.30 1.65 2.15
5 1,882 2,440 0.75 1.70 1.08 0.74 0.80
6 1,588 1,540 0.52 1.90 1.29 0.89 1.14
7 1,367 1,450 0.50 2.31 1.55 0.92 1.43
Mean 6 SD 1,386 6 298 1,460 6 472 0.50 (median) 2.056 0.50 1.49 6 0.42 1.18 6 0.38 1.77 6 0.70
8 1,284 1,230 0.50 1.95 1.67 1.28 2.13
ZDV (200 mg oral) 1 1,539 1,590 0.25 2.44 1.72 1.87 0.60
2 1,685 1,770 0.75 1.71 2.01 2.01 0.86
3 1,776 1,890 0.50 2.04 1.74 1.38 0.90
4 1,572 1,550 0.50 2.61 2.18 1.74 0.95
5 2,018 1,760 0.75 1.55 2.10 1.15 0.64
6 1,680 2,060 0.52 1.88 1.44 1.37 0.65
7 1,421 1,640 0.52 2.04 1.96 1.48 0.62
Mean 6 SD 1,670 6 192 1,751 6 180 0.52 (median) 2.046 0.38 1.88 6 0.26 1.57 6 0.31 0.75 6 0.15
8 2,630 1,980 1.00 2.05 2.15 1.04 1.23
a Abbreviations: MRT, mean residence time; Vss, volume of distribution at steady state.
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The apparent t1/2s of GZDV were 1.71 6 0.31 and 1.45 6 0.12
h after i.v. and oral ZDV administration, respectively. Since
GZDV appears to be formation rate limited, these values for
the apparent t1/2 of GZDV do not represent the true GZDV
t1/2.
DISCUSSION
The pharmacokinetics of ZDV and GZDV are altered in
patients with hepatic disease. Table 4 shows comparative phar-
macokinetic parameters of ZDV and GZDV in patients and
volunteers with and without liver disease. All patients in the
present study (AIDS Clinical Trials Group Protocol 062, Table
4), even those classified with mild hepatic impairment (seven
of eight patients), had pharmacokinetic parameters that varied
from those reported in healthy volunteers and HIV-infected
patients without hepatic disease.
This discussion will focus on pharmacokinetic parameters
after oral administration, since this is the most common route
of ZDV administration, and there are extensive comparative
data for this route of administration. After oral administration
of ZDV to patients with liver disease in the present study,
mean CL/F of ZDV (121.1 6 13.4 liters/h) was less than that
reported in HIV-infected men without liver disease (152.82 6
61.38 liters/h) or in HIV-negative healthy subjects (153.72 6
48.8 liters/h) (6, 21). Singlas and associates (21) concluded that
the ‘‘pharmacokinetics of ZDV in healthy subjects is similar to
that in HIV-seropositive patients with normal renal and he-
patic function.’’ Fletcher et al. compared the pharmacokinetics
of ZDV in healthy volunteers (n5 6) with that in patients with
AIDS (n 5 6). After administration of a single 200-mg oral
dose of ZDV, CL/Fs were 2.04 6 0.46 and 1.78 6 0.38 liters/
h/kg for healthy volunteers and patients with AIDS, respec-
tively (8). The ZDV CL/F in eight HIV-infected patients with
hemophilia and mild hepatic impairment (Child-Pugh score,
>5) given a single 300-mg oral dose was 1.686 0.90 liters/h/kg,
which is similar to the value reported in the present study (13).
After 12 weeks of ZDV administration in five of the patients
described above, the CL/F (1.63 6 0.65 liters/h/kg) was rela-
tively unchanged (14). The report by Morse et al. (14), as well
as data from the present study, indicates that patients with mild
liver disease cleared ZDV more slowly than HIV-positive or
HIV-negative subjects without liver dysfunction.
The t1/2s after oral dosing of ZDV in HIV-infected men and
in healthy subjects were 1.04 6 0.37 and 1.0 6 0.20 h, respec-
tively (6, 21). The ZDV t1/2 in our study was prolonged (2.046
0.38 h), which is consistent with the t1/2 reported by Taburet et
al. for HIV-negative patients with various degrees of liver
cirrhosis (2.46 1.2 h) and inconsistent with reports by Fletcher
et al. and Morse et al. (8, 13, 22). Fletcher and colleagues
reported a t1/2 of 1.24 6 0.20 h in patients with AIDS and
unclassified moderate-to-severe hepatic disease (n 5 3). The
sampling scheme used by Fletcher et al., with the last collection
time at 6 h, may have led to an underestimation of t1/2 in this
population. In the hemophiliac patients with mild hepatic im-
pairment studied by Morse et al., the mean t1/2s were 1.3 6 0.5
h (n5 3) in patients showing biexponential elimination and 4.8
6 2.8 h (n 5 5) in patients showing triexponential elimination.
However, the longer t1/2 was calculated from only two datum
points from three patients (13). Although the reported values
appear to vary greatly, our results support a slightly prolonged
t1/2 in patients with hepatic dysfunction.
After an oral dose of 200 mg as capsules, peak concentra-
tions were elevated in the present study (1,751 6 180 ng/ml),
compared with results reported by Taburet et al. in normal
volunteers (1,067 6 293 ng/ml), and less than the mean peak
concentration in patients with biopsy-proven cirrhosis (2,8806
1,467 ng/ml) (22). F was slightly increased (75%6 15%) in our
patients with mild hepatic disease compared with historical
values of approximately 64% (1).
In the present study, of seven patients with mild hepatic
dysfunction given oral ZDV, the Cmax and AUC of GZDV and
the AUC ratio of GZDV to ZDV were reduced by approxi-
mately 21, 26, and 40%, respectively, compared with those of
HIV-seronegative healthy volunteers (21). Clearly, less GZDV
TABLE 3. Pharmacokinetic parameters of GZDV after ZDV administration
Treatment Patient AUC0–`(ng z h/ml)
Cmax
(ng/ml) Tmax (h) MRT (h)
a AUCGZDV/AUCZDV
ZDV (120 mg i.v.) 1 3,205 1,350 0.79 2.18 1.26
2 2,475 1,680 0.75 1.87 1.26
3 2,356 1,190 0.73 2.11 1.19
4 3,634 2,390 0.50 2.09 2.20
5 3,341 1,620 0.75 2.13 1.07
6 2,343 1,290 0.52 1.75 0.91
7 1,925 1,330 0.50 1.46 0.84
Mean 6 SD 2,754 6 634 1,550 6 411 0.73 (median) 1.94 6 0.26 1.25 6 0.45
8 1,846 2,110 0.25 0.80 0.87
ZDV (200 mg oral) 1 7,537 3,310 0.78 2.18 3.00
2 9,052 7,000 1.08 1.82 3.24
3 7,687 6,290 0.50 1.64 2.61
4 8,900 6,130 0.75 1.83 3.41
5 8,106 4,190 1.00 2.49 2.42
6 7,073 5,420 0.77 1.52 2.54
7 5,440 4,200 0.77 1.65 2.31
Mean 6 SD 7,685 6 1,222 5,220 6 1,350 0.77 (median) 1.88 6 0.34 2.79 6 0.43
8 3,465 1,940 1.00 2.18 0.79
aMRT, mean residence time.
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metabolite is formed in patients with hepatic impairment. Al-
though only one patient (patient 8) had moderate hepatic
dysfunction with evidence of portal hypertension, it is interest-
ing to note he had the lowest AUC ratio of GZDV to ZDV
(0.79). Likewise, the GZDV AUC (3,465 ng z h/ml) in this
patient was relatively small. The mean apparent t1/2 (1.45 6
0.12 h) of GZDV was increased in the patients studied com-
pared with that of healthy subjects (22). The elimination of
GZDV is rate limited by its formation, as evidenced by its
parallel decay with ZDV. Again, these results are consistent
with previous data suggesting impaired ZDV elimination in
hepatic disease (8, 13, 22).
The results of the present study show that the hepatic me-
tabolism of ZDV is impaired in patients with mild hepatic
dysfunction. The glucuronidation of ZDV is catalyzed by
UDP-glucuronosyltransferase (UDPGT) (17). At least five dif-
ferent human UDPGT isozymes are known, and several forms
have yet to be adequately characterized (25). Existing data
suggest that UDPGT2 is involved primarily in ZDV glucuron-
idation in humans (16). Endogenous compounds that accumu-
late in cirrhosis and hepatitis and are substrates for this
isozyme of UDPGT may interfere with ZDV glucuronidation
(24).
Drug disposition can be altered in hepatic disease because of
changes in hepatic blood flow, enzyme activity (amount of
available enzymes), plasma protein binding, or the develop-
ment of portosystemic shunts. The pharmacokinetic differ-
ences observed in asymptomatic HIV-infected patients with
liver dysfunction may have an impact on ZDV dosing during
extended therapy. Seven of the patients studied in this report
had only mild hepatic impairment, and yet differences in ex-
posure (on the basis of the AUC and Cmax) and elimination
were observed. In general, increased Cmax, increased AUC,
decreased CL/F, and a slightly prolonged t1/2 were observed in
this population. These results suggest that a dose reduction or
extended dosing intervals may be necessary in patients with
liver dysfunction to diminish the risk of ZDV toxicity which has
been associated with elevated concentrations of ZDV in se-
rum.
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